TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
3320 Stock 12 Month Forecast
There Are No Analyst Ratings for HK:3320 In The Last 3 Months.
Highest Price Target―
Average Price Target―
Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
3320 Financial Forecast
3320 Earnings Forecast
Next quarter’s earnings estimate for 3320 is HK$0.43 with a range of HK$0.43 to HK$0.43. The previous quarter’s EPS was HK$0.13. 3320 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 3320 has its overall industry.
Next quarter’s earnings estimate for 3320 is HK$0.43 with a range of HK$0.43 to HK$0.43. The previous quarter’s EPS was HK$0.13. 3320 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 3320 has its overall industry.
3320 Sales Forecast
Next quarter’s sales forecast for 3320 is HK$140.96B with a range of HK$140.96B to HK$140.96B. The previous quarter’s sales results were HK$140.02B. 3320 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 3320 has its overall industry.
Next quarter’s sales forecast for 3320 is HK$140.96B with a range of HK$140.96B to HK$140.96B. The previous quarter’s sales results were HK$140.02B. 3320 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 3320 has its overall industry.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$6.8
Buy
47.51%
Upside
Reiterated
10/14/25
Unknown Analyst
China Merchants Securities
Not Ranked
China Merchants Securities
HK$5.9
Buy
27.98%
Upside
Reiterated
09/01/25
Unknown Analyst
CICC
Not Ranked
CICC
HK$7
Buy
51.84%
Upside
Reiterated
08/29/25
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$5.7
Buy
23.64%
Upside
Reiterated
08/27/25
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$7
Buy
51.84%
Upside
Reiterated
06/16/25
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$6.8→HK$5.9
Buy
27.98%
Upside
Reiterated
04/07/25
China Resource Pharamaceutical Group (3320:HK) PT Lowered to HK$5.90 at CLSACLSA analyst David Dong lowered the price target on China Resource Pharamaceutical Group (3320:HK) to HK$5.90 (from HK$6.80) while maintaining a Outperform (2) rating.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$6.8
Buy
47.51%
Upside
Reiterated
10/14/25
Unknown Analyst
China Merchants Securities
Not Ranked
China Merchants Securities
HK$5.9
Buy
27.98%
Upside
Reiterated
09/01/25
Unknown Analyst
CICC
Not Ranked
CICC
HK$7
Buy
51.84%
Upside
Reiterated
08/29/25
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$5.7
Buy
23.64%
Upside
Reiterated
08/27/25
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$7
Buy
51.84%
Upside
Reiterated
06/16/25
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$6.8→HK$5.9
Buy
27.98%
Upside
Reiterated
04/07/25
China Resource Pharamaceutical Group (3320:HK) PT Lowered to HK$5.90 at CLSACLSA analyst David Dong lowered the price target on China Resource Pharamaceutical Group (3320:HK) to HK$5.90 (from HK$6.80) while maintaining a Outperform (2) rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.
3320 Analyst Recommendation Trends
Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
0
0
0
0
0
Buy
3
4
2
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
4
2
1
0
In the current month, 3320 has received 0Buy Ratings, 0Hold Ratings, and 0Sell Ratings. 3320 average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
3320 Stock Forecast FAQ
What is HK:3320’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:3320’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:3320, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is China Resources Pharmaceutical Group Ltd. a Buy, Sell or Hold?
Currently, no data Available
What is China Resources Pharmaceutical Group Ltd.’s share price target?
Currently, no data Available
What do analysts say about China Resources Pharmaceutical Group Ltd.?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of China Resources Pharmaceutical Group Ltd.?
To buy shares of HK:3320, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.